Physician profile
Laszlo A Feher
NPI 1205932290
$4,018.73
in general payments reported to CMS, 2019-2025
28 companies · $849 in 2025
The $849 reported for 2025 was more than what 87% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $910 · 2020: $256 · 2021: $370 · 2022: $523 · 2023: $380 · 2024: $730 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,959.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $716.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $345.32 | 2019-2025 | |
| Lilly USA, LLC | $323.37 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| E.R. Squibb & Sons, L.L.C. | $313.74 | 2019-2024 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $289.79 | 2021-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $285.50 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.18 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $232.97 | 2019-2023 | Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $223.19 | 2019-2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.53 | 2022-2023 | Jardiance |
| Bausch Health US, LLC | $168.44 | 2022-2025 | Aplenzin, Wellbutrin |
| Abbvie INC. | $133.08 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $123.43 | 2019-2021 | |
| Amgen INC. | $59.78 | 2019 | |
| Merck Sharp & Dohme LLC | $55.47 | 2021-2024 | Dificid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $50.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $45.97 | 2019-2020 | |
| Mylan Specialty L.P. | $32.00 | 2019 | |
| Currax Pharmaceuticals LLC | $29.87 | 2024-2025 | Contrave |
| Sumitomo Pharma America, INC. | $28.42 | 2025 | Gemtesa |
| Shield Therapeutics INC | $27.83 | 2025 | |
| Philips North America LLC | $27.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.78 | 2022 | |
| Mannkind Corporation | $17.27 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.90 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.37 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.24 | 2021 | |
| Genentech USA, INC. | $15.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laszlo Feher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.